Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 111 clinical trials
featured
Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes

Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes

  • 230 views
  • 08 Nov, 2020
  • 1 location
featured
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes

  • 286 views
  • 08 Nov, 2020
  • 1 location
Regulation of Insulin Secretion by the GLP-1 Receptor

AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance. Healthy subjects will have fasting GLP-1 action determined with GLP-1r blockade before and after induction of experimental insulin resistance. The investigators hypothesize that fasting GLP-1 action …

  • 0 views
  • 27 Dec, 2020
  • 2 locations
Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

The aim of this study is to determine if early and tight restoration of metabolic control at the onset of Type 1 diabetes (T1DM) will improve insulin secretion (C-peptide production

  • 182 views
  • 07 Nov, 2020
  • 3 locations
The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)

function as compared to age matched controls. Primary objective of the trial is the change in C-peptide area under the curve measured by mixed-meal tolerance test (MMTT) between group on GFD and standard

tolerance test
diabetes
c-peptide
  • 25 views
  • 08 Nov, 2020
  • 2 locations
Liraglutide in Type 1 Diabetes

mean and standard deviation of blood glucose, HbA1c and insulin requirements. Since C-peptide concentrations did not alter following Liraglutide, it is likely that the suppression of glucagon may

type 2 diabetes mellitus
liraglutide
glycosylated hemoglobin
insulin
glucagon
  • 87 views
  • 08 Nov, 2020
  • 1 location
Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes

The primary objective of the study is: - To compare the effect of ATG treatment together with intensified insulin therapy (Group 1) on fasting and glucagon-stimulated C-peptide

body mass index
diabetes
fasting
autoimmune disease
insulin
  • 16 views
  • 07 Nov, 2020
  • 1 location
Multiple Dose Study to Evaluate the Efficacy Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

diagnosed with Type 1 diabetes with fasting C-peptide < 0.7 ng/mL at Screening. The study will be conducted at multiple sites in the United States. Approximately 150 subjects with type 1

  • 866 views
  • 21 Oct, 2020
  • 11 locations
DFMO in Children With Type 1 Diabetes

patients with new onset type 1 diabetes with documented continued residual C-peptide production. After a 4 week screening and run-in period during which eligibility will be determined and glycemic control

fasting c-peptide level
fasting
diabetes
c-peptide
  • 72 views
  • 08 Nov, 2020
  • 3 locations
Effects of Sucralose in Insulin Sensitivity Intestinal Microbiota and Postprandial GLP-1

a low grade inflammation known as metabolic endotoxemia. In addition, the changes in postprandial concentrations of GLP-1, glucose, insulin and C-peptide due to the combination of sucralose with a

  • 0 views
  • 08 Dec, 2019
  • 1 location